US EditionElixir Medical’s DynamX Studied at 3 Years in BIOADAPTOR RCT - Cardiac Interventions Today
Summary by Cardiac Interventions Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Elixir Medical’s DynamX Studied at 3 Years in BIOADAPTOR RCT - Cardiac Interventions Today
May 30, 2025—Elixir Medical recently announced 3-year results from the BIOADAPTOR randomized controlled trial (RCT) comparing the company’s DynamX coronary sirolimus-eluting bioadaptor system to the standard-of-care Resolute Onyx zotarolimus drug-eluting stent (DES; Medtronic). The study was composed of 445 patients enrolled at 34 centers in Japan, Europe, and New Zealand. According to the company, the results demonstrated sustained low adverse …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
